Stuttgart - Delayed Quote EUR

Anavex Life Sciences Corp (12X1.SG)

7.76

+0.22

+(2.97%)

At close: April 17 at 9:47:21 PM GMT+2

Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ...

Anavex Life Sciences Corp (AVXL) showcases significant clinical advancements and strategic patent extensions amidst financial challenges and market expansion plans.

GuruFocus.com 7 hours ago

AVXL
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute a

GlobeNewswire 16 hours ago

AVXL
High Growth Tech Stocks To Watch In The US Market

Over the last 7 days, the United States market has experienced a drop of 9.4%, contributing to a 3.4% decline over the past year, although earnings are forecast to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies with strong fundamentals and innovative capabilities that can thrive despite current market challenges.

Simply Wall St. 14 days ago

OLO

AUPH

AVXL
AD/PD 2025: Long-term data shows Anavex’s Blarcamesine benefits in early Alzheimer’s

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology, providing neuroprotective effects.

Clinical Trials Arena 14 days ago

AVXL
Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years

Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. ATTENTION-AD (ANAVEX 2-73-AD-EP-004) trial result was presented at the AD/PDTM 2025 Conference. Continued blarcamesine treatment for up to four (4) years demonstrated a good comparative safety profile and no

Benzinga 14 days ago

AVXL
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company

GlobeNewswire 16 days ago

AVXL
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7

GlobeNewswire 21 days ago

AVXL
Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has dropped 2.7%, but it has shown resilience with an 11% rise over the past year and earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive longer-term trends.

Simply Wall St. last month

AVXL

SRPT

VERX
Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Expected To Breakeven In The Near Future

Anavex Life Sciences Corp. ( NASDAQ:AVXL ) is possibly approaching a major achievement in its business, so we would...

Simply Wall St. last month

AVXL
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025

GlobeNewswire last month

AVXL
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

NEW YORK (AP) — Anavex Life Sciences Corp. AVXL) on Wednesday reported a loss of $12.1 million in its fiscal first quarter. On a per-share basis, the New York-based company said it had a loss of 14 cents.

Associated Press Finance 2 months ago

AVXL
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first

GlobeNewswire 2 months ago

AVXL
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ETNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it w

GlobeNewswire 2 months ago

AVXL
Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Anavex Life Sciences Corp. (NASDAQ:AVXL) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns about the uncertain economic outlook for 2025, particularly […]

Insider Monkey 2 months ago

AVXL

^GSPC
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COM

GlobeNewswire 2 months ago

AVXL
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

Zacks 2 months ago

AVXL
Best Momentum Stocks to Buy for January 21st

CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.

Zacks 2 months ago

CDNA

ALNY

AVXL
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer’s disease NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Par

GlobeNewswire 3 months ago

AVXL
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatm

GlobeNewswire 3 months ago

AVXL
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, J

GlobeNewswire 3 months ago

AVXL

Performance Overview

Return	12X1.SG	S&P 500 (^GSPC)
YTD	-33.81%	-12.30%
1-Year	+127.08%	+3.84%
3-Year	-18.04%	+17.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Anavex Life Sciences Corp (12X1.SG)

Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ...

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

High Growth Tech Stocks To Watch In The US Market

AD/PD 2025: Long-term data shows Anavex’s Blarcamesine benefits in early Alzheimer’s

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Exploring 3 High Growth Tech Stocks In The US Market

Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Expected To Breakeven In The Near Future

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

Best Momentum Stocks to Buy for January 21st

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview